A single arm pilot study of azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia

Trial Profile

A single arm pilot study of azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Azacitidine (Primary) ; Eltrombopag (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms AZA-E
  • Most Recent Events

    • 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Oct 2013 Planned end date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
    • 08 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top